

Supplementary Table 1 All patients were randomly divided into training (70%) and validation (30%) cohorts using the R software sample function

Variables	Total (<i>n</i> = 299)	Training (<i>n</i> = 209)	Validation (<i>n</i> = 90)	Z	P value
FFS Outcome				0.610	0.435
Negative	87 (29.1)	58 (27.8)	29 (32.2)		
Positive	212 (70.9)	151 (72.2)	61 (67.8)		
	25.00	25.00	26.00		
time, Median (Q1,Q3)	(17.00, 36.00)	(16.00, 36.00)	(18.25, 36.00)	-0.972	0.331
Group				5.339	0.069
PSOX	118 (39.5)	91 (43.5)	27 (30.0)		
SOX	100 (33.4)	63 (30.1)	37 (41.1)		
SOX+XDL	81 (27.1)	55 (26.3)	26 (28.9)		
Age				0.009	0.926
≤ 60	164 (54.8)	115 (55.0)	49 (54.4)		
> 60	135 (45.2)	94 (45.0)	41 (45.6)		
Gender				0.311	0.577
Male	240 (80.3)	166 (79.4)	74 (82.2)		
Female	59 (19.7)	43 (20.6)	16 (17.8)		
ASA				2.822	0.093
1 + 2	261 (87.3)	178 (85.2)	83 (92.2)		
3	38 (12.7)	31 (14.8)	7 (7.8)		
differentiation				3.061	0.216
Well	82 (27.4)	58 (27.8)	24 (26.7)		
Moderate	80 (26.8)	50 (23.9)	30 (33.3)		
Poorly	137 (45.8)	101 (48.3)	36 (40.0)		
cT stage				8.140	0.017

2	71 (23.7)	40 (19.1)	31 (34.4)		
3	155 (51.8)	115 (55.0)	40 (44.4)		
4	73 (24.4)	54 (25.8)	19 (21.1)		
cN stage				0.007	0.933
Negative	92 (30.8)	64 (30.6)	28 (31.1)		
Positive	207 (69.2)	145 (69.4)	62 (68.9)		
cTNM				6.739	0.081
II	148 (49.5)	103 (49.3)	45 (50.0)		
IIIA	28 (9.4)	14 (6.7)	14 (15.6)		
IIIB	62 (20.7)	47 (22.5)	15 (16.7)		
IIIC	61 (20.4)	45 (21.5)	16 (17.8)		
RECIST1.1				0.099	0.753
Ineffective	117 (39.1)	83 (39.7)	34 (37.8)		
Effective	182 (60.9)	126 (60.3)	56 (62.2)		
Nausea and vomiting				Fisher	0.704
0	63 (21.1)	47 (22.5)	16 (17.8)		
1	171 (57.2)	115 (55.0)	56 (62.2)		
2	58 (19.4)	42 (20.1)	16 (17.8)		
3	7 (2.3)	5 (2.4)	2 (2.2)		
Liver toxicity				Fisher	0.774
0	254 (84.9)	176 (84.2)	78 (86.7)		
1	39 (13.0)	29 (13.9)	10 (11.1)		
2	6 (2.0)	4 (1.9)	2 (2.2)		
alopecia				Fisher	0.621
0	178 (59.5)	128 (61.2)	50 (55.6)		
1	107 (35.8)	72 (34.4)	35 (38.9)		
2	14 (4.7)	9 (4.3)	5 (5.6)		
Peripheral				Fisher	0.173

sensory				
neuropathy				
0	143 (47.8)	102 (48.8)	41 (45.6)	
1	124 (41.5)	81 (38.8)	43 (47.8)	
2	27 (9.0)	23 (11.0)	4 (4.4)	
3	5 (1.7)	3 (1.4)	2 (2.2)	
Fewer				
neutrophils				Fisher 0.583
0	218 (72.9)	149 (71.3)	69 (76.7)	
1	52 (17.4)	40 (19.1)	12 (13.3)	
2	18 (6.0)	11 (5.3)	7 (7.8)	
3	10 (3.3)	8 (3.8)	2 (2.2)	
4	1 (0.3)	1 (0.5)	0 (0.0)	
Fewer white				
blood cells				Fisher 0.961
0	196 (65.6)	136 (65.1)	60 (66.7)	
1	66 (22.1)	45 (21.5)	21 (23.3)	
2	26 (8.7)	20 (9.6)	6 (6.7)	
3	7 (2.3)	5 (2.4)	2 (2.2)	
4	4 (1.3)	3 (1.4)	1 (1.1)	
Fewer				
platelets				Fisher 1.000
0	215 (71.9)	149 (71.3)	66 (73.3)	
1	54 (18.1)	38 (18.2)	16 (17.8)	
2	25 (8.4)	18 (8.6)	7 (7.8)	
3	5 (1.7)	4 (1.9)	1 (1.1)	
Anemia				Fisher 0.945
0	152 (50.8)	108 (51.7)	44 (48.9)	
1	106 (35.5)	72 (34.4)	34 (37.8)	

2	26 (8.7)	18 (8.6)	8 (8.9)		
3	15 (5.0)	11 (5.3)	4 (4.4)		
Laurnen				0.048	0.976
Diffuse	107 (35.8)	75 (35.9)	32 (35.6)		
Mixed	141 (47.2)	99 (47.4)	42 (46.7)		
Intestinal	51 (17.1)	35 (16.7)	16 (17.8)		
Tumor					
location				5.251	0.072
Upper	75 (25.1)	60 (28.7)	15 (16.7)		
Middle	116 (38.8)	75 (35.9)	41 (45.6)		
Lower	108 (36.1)	74 (35.4)	34 (37.8)		
TRG				0.109	0.741
Effective	262 (87.6)	184 (88.0)	78 (86.7)		
Ineffective	37 (12.4)	25 (12.0)	12 (13.3)		
tumor					
diameter				0.264	0.876
≤ 2	156 (52.2)	108 (51.7)	48 (53.3)		
2-5	79 (26.4)	57 (27.3)	22 (24.4)		
≥ 5	64 (21.4)	44 (21.1)	20 (22.2)		

ASA: American Society of Anesthesiologists Score; RECIST: Response evaluation criteria in solid tumors; TRG: Tumor regression grade; XDL: Sintilimab.